skip to primary navigationskip to content


Figure 1. Clinical responses of advanced metastatic melanoma patients to immune checkpoint inhibitor therapy. Progression-free survival (RECIST criteria) of patients with advanced melanoma at a median follow-up of 2 years in all patients assigned to treatment. Responses of individuals randomised to either anti-CTLA-4 (ipilimumab), or combined anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) treatment groups are shown. Data from Hodi et al., Lancet Oncol 2016)
Full-size image: 109 KB | View imageView Download imageDownload

Advice for staff and students at the University and Colleges on novel coronavirus (COVID-19). The University is continually monitoring latest Public Health England and government advice about the virus.

Read more

Safe Space Information

In collaboration with the University Safe Space team, the department has generated a Return to the Workplace document that outlines the current social distancing measures which are in place to protect the safety and welfare of you and others. This document is updated frequently as guidance changes.